Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.

Détails

ID Serval
serval:BIB_B17AAA9FB2DA
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.
Périodique
Future Oncology
Auteur(s)
Reardon D.A., Neyns B., Weller M., Tonn J.C., Nabors L.B., Stupp R.
ISSN
1744-8301 (Electronic)
ISSN-L
1479-6694
Statut éditorial
Publié
Date de publication
2011
Volume
7
Numéro
3
Pages
339-354
Langue
anglais
Résumé
Cilengitide, a cyclicized arginine-glycine-aspartic acid-containing pentapeptide, potently blocks ανβ3 and ανβ5 integrin activation. Integrins are upregulated in many malignancies and mediate a wide variety of tumor-stroma interactions. Cilengitide and other integrin-targeting therapeutics have preclinical activity against many cancer subtypes including glioblastoma (GBM), the most common and deadliest CNS tumor. Cilengitide is active against orthotopic GBM xenografts and can augment radiotherapy and chemotherapy in these models. In Phase I and II GBM trials, cilengitide and the combination of cilengitide with standard temozolomide and radiation demonstrate consistent antitumor activity and a favorable safety profile. Cilengitide is currently under evaluation in a pivotal, randomized Phase III study (Cilengitide in Combination With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma Phase III Randomized Clinical Trial [CENTRIC]) for newly diagnosed GBM. In addition, randomized controlled Phase II studies with cilengitide are ongoing for non-small-cell lung cancer and squamous cell carcinoma of the head and neck. Cilengitide is the first integrin inhibitor in clinical Phase III development for oncology.
Pubmed
Web of science
Création de la notice
13/05/2011 9:22
Dernière modification de la notice
20/08/2019 15:20
Données d'usage